Pharma’s Almanac: How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

Alicia Castillo Holley hosts Jason Bock on her show. Curative Intent: on Engineering T-Cells, Patient Impact, and Chasing the Impossible. The...

By Jason Bock, Ph.D., CEO, and Duane Avant, CTO, CTMC Manufacturing autologous cell therapies requires close coordination with clinical staff, as...

Read the full article here: Pharma's Almanac